2 papers4 findings
KDMAge acceleration
upin humans1HR 1.22
KDMAge acceleration is associated with cardiovascular-kidney-metabolic syndrome progression to stage 4 in humans (HR 1.220, 95% CI 1.207–1.232 per 1-SD increment).
“KDMAge acceleration showed corresponding HRs of 1.229 (95% CI 1.180-1.280) and 1.220 (95% CI 1.207-1.232), all P < 0.001.”
HumansUK Biobank participants initially at stage 1 or 2/3Per 1-SD incrementMedian 13.48 years
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
PhenoAge
upin humans1HR 1.208
PhenoAge is associated with cardiovascular-kidney-metabolic syndrome progression to stage 4 in humans (HR 1.208, 95% CI 1.197–1.218 per 1-SD increment).
“PhenoAge acceleration was associated with both transitions [hazard ratios (HRs) 1.234, 95% confidence interval (CI) 1.189-1.281; HR 1.208, 95% CI 1.197-1.218].”
HumansUK Biobank participants initially at stage 1 or 2/3Per 1-SD incrementMedian 13.48 years
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
Elevated TyG combined with reduced NCCR
upin humans1
Elevated TyG combined with reduced NCCR is associated with cardiovascular-kidney-metabolic syndrome progression to stage 4 in humans.
“the combination of elevated TyG and reduced NCCR, reflecting a “metabolic‐structural uncoupling” phenotype, was significantly correlated with heightened risk of CKM progression.”
HumansJoint exposure analysis
Combined blood marker linked to cardiovascular disease risk
Cardiovascular diabetology9 Oct 2026
TyG-NCCR
upin humans1HR 1.2
TyG-NCCR predicts cardiovascular-kidney-metabolic syndrome progression to stage 4 in humans (HR 1.20, 95% CI 1.13–1.29 per SD increase).
“each SD increase in TyG-NCCR was associated with higher risk of CKM progression in CHARLS (HR: 1.20, 95% CI: 1.13–1.29; p < 0.001)”
HumansCHARLS participants at CKM stages 0–3 at baseline; adjusted models; per SD increase in TyG-NCCR2011 to 2020n = 5,474
Combined blood marker linked to cardiovascular disease risk
Cardiovascular diabetology9 Oct 2026
Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.
An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.